Trial Data Showed Eltrombopag Decreased Bleeding Episodes And Improved Platelet Counts In Patients With Chronic Idiopathic Thrombocytopenic Purpura
Sat, 16 Dec 2006 12:00 PM EST
... GlaxoSmithKline (GSK) has announced additional results from an international Phase II short-term, six-week study of its investigational non-peptide oral platelet growth factor, eltrombopag*. [click link for full article] ...
Related Topics
- Bleeding Disorders
- Idiopathic Thrombocytopenia Purpura
- Thrombocytopenia
- Clinical Trials
- Data & Statistics
- Platelet Count
- Immune Thrombocytopenic Purpura (ITP)
- Data Analysis
- Platelet Function
- National Data
- Hives
- Chronic Fatigue Syndrome
- Gastrointestinal Bleeding
- Chronic Pain
- Pain - Chronic
- Chronic Diseases
- Mining
- Decreased production tears
- Decreased tear production
- Vaccinations For HIV/AIDs Patients

Not Signed In -


